<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961816</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0074</org_study_id>
    <secondary_id>NCI-2016-01914</secondary_id>
    <nct_id>NCT02961816</nct_id>
  </id_info>
  <brief_title>Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma</brief_title>
  <official_title>Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the safety and effectiveness of
      the combination of panobinostat, gemcitabine, busulfan, and melphalan, either with or without
      rituximab, in patients who have non-Hodgkin's or Hodgkin's lymphoma and are receiving a stem
      cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan Test Dose:

      Participant will receive a test dose of busulfan by vein over about 60 minutes. Before and
      after participant receives this low-level test dose of busulfan, blood will be drawn several
      times to check how the level of busulfan in participant's blood changes over time. This is
      called pharmacokinetic (PK) testing. This information will be used to decide the next dose
      needed to reach the correct blood level that matches participant's body size. Participant
      will most likely receive this test dose as an outpatient during the week before participant
      is admitted to the hospital. If it cannot be given as an outpatient, participant will be
      admitted to the hospital on Day -11 (11 days before participant's stem cells are returned to
      participant's body) and the test dose will be given on Day -10.

      Blood (about 1 teaspoon each time) will be drawn for PK testing about 11 times before
      participant's test dose of busulfan and 10 times over the 11 hours after the dose. The blood
      samples will be repeated again on the first day of high-dose busulfan treatment (Day -8). A
      temporary heparin lock line will be placed in participant's vein to lower the number of
      needle sticks needed for these draws.

      If it is not possible for the PK tests to be performed for any reason, participant will
      receive the standard fixed dose of busulfan.

      Study Drug Administration:

      On Days -13 through -11 (the 3 days before participant is admitted to the hospital),
      participant will receive palifermin by vein over about 30 seconds each day to help decrease
      the risk of side effects in the mouth and throat.

      On Day -9 through Day -2, participant will take panobinostat by mouth, with food. The study
      staff will tell participant how many tablets to take. Participant will receive dexamethasone
      by vein over about 3-5 minutes 2 times each day.

      On Day -9, if participant has a type of B-cell cancer, participant will receive rituximab (a
      treatment used for certain lymphomas) by vein over about 3-6 hours as part of participant's
      standard care. The study doctor will tell participant if participant will receive rituximab.

      On Day -8, participant will receive gemcitabine by vein over 4½ hours.

      On Days -8, -7, -6, and -5, participant will receive busulfan by vein over about 60 minutes.

      On Day -3, participant will receive gemcitabine by vein over 4½ hours and then melphalan by
      vein over 30 minutes.

      On Day -2, participant will receive melphalan by vein over 30 minutes.

      On Day -1, participant will rest (participant will not receive chemotherapy).

      On Day 0, participant will receive participant's stem cells by vein over about 30-60 minutes.

      Participant will receive 3 more doses of palifermin by vein, over 15-30 seconds each time, on
      Days 0, +1, and +2.

      As part of standard care, participant will receive G-CSF (filgrastim) as an injection just
      under participant's skin 1 time each day starting on Day +5 until participant's blood cell
      levels return to normal. The study doctor will discuss this with participant, including how
      filgrastim is given and its risks.

      Length of Study:

      As part of standard care, participant will remain in the hospital for about 3-4 weeks after
      the transplant. After participant is released from the hospital, participant will continue as
      an outpatient. Participant will need to stay in the Houston area to be checked for infections
      and side effects.

      Participant will be taken off study about 100 days after the transplant. Participant may be
      taken off study earlier if the disease gets worse, if intolerable side effects occur, or if
      participant is unable to follow study directions.

      Study Tests:

      About 100 days after the transplant:

        -  Participant will have a physical exam.

        -  Blood (about 4 teaspoons) and urine will be collected for routine tests.

        -  If the doctor thinks it is needed, participant may have a bone marrow aspiration and
           biopsy to check the status of the disease. To collect a bone marrow aspiration/biopsy,
           an area of the hip is numbed with anesthetic, and a small amount of bone marrow and bone
           is withdrawn through a large needle.

      This is an investigational study. Panobinostat and melphalan are FDA approved and
      commercially available for the treatment of multiple myeloma (MM). Busulfan is FDA approved
      and commercially available for the treatment of leukemia. Gemcitabine is FDA approved and
      commercially available for the treatment of lymphoma, breast cancer, and lung cancer.
      Rituximab is FDA approved and commercially available for the treatment of non-Hodgkin's
      lymphoma.

      The use of these study drugs in combination is investigational. The study doctor can explain
      how the study drugs are designed to work.

      Up to 75 participants will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free Survival (EFS) in Participants with Diffuse Large B-Cell Lymphoma</measure>
    <time_frame>2 years</time_frame>
    <description>EFS estimated by using the method of Kaplan and Meier.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS) in Participants with Hodgkin's Lymphoma</measure>
    <time_frame>2 years</time_frame>
    <description>EFS estimated by using the method of Kaplan and Meier.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS) in Participants with T-Cell Lymphoma</measure>
    <time_frame>2 years</time_frame>
    <description>EFS estimated by using the method of Kaplan and Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Mortality (TRM)</measure>
    <time_frame>100 days</time_frame>
    <description>(TRM) monitored by using the method of Thall, Simon, and Estey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>100 days</time_frame>
    <description>OS estimated by using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat daily from Day -9 to -2.
Gemcitabine administered on Days -8 and -3.
Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan on Days -3 and -2.
Rituximab on Day -9 for participants with CD20+ tumors.
Dexamethasone twice a day from Day -8 AM to Day -2 PM.
Caphosol oral rinses 30 mL four times a day used from Day -8.
Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Pyridoxine three times a day from Day -1.
Stem cells administered by vein on Day 0.
G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat daily from Day -9 to -2.
Gemcitabine administered on Days -8 and -3.
Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan on Days -3 and -2.
Rituximab on Day -9 for participants with CD20+ tumors.
Dexamethasone twice a day from Day -8 AM to Day -2 PM.
Caphosol oral rinses 30 mL four times a day used from Day -8.
Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Pyridoxine three times a day from Day -1.
Stem cells administered by vein on Day 0.
G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
Panobinostat daily from Day -9 to -2.
Gemcitabine administered on Days -8 and -3.
Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Melphalan on Days -3 and -2.
Rituximab on Day -9 for participants with CD20+ tumors.
Dexamethasone twice a day from Day -8 AM to Day -2 PM.
Caphosol oral rinses 30 mL four times a day used from Day -8.
Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Pyridoxine three times a day from Day -1.
Stem cells administered by vein on Day 0.
G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>20 mg by mouth daily from Day -9 to -2.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>LBH589B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Gemcitabine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan &quot;test dose&quot; administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>60 mg/m2 by vein on Days -3 and -2.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>8 mg by vein twice a day from Day -8 AM to Day -2 PM.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caphosol</intervention_name>
    <description>Caphosol oral rinses 30 mL four times a day used from Day -8.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Enterex</other_name>
    <other_name>Glutapak-10</other_name>
    <other_name>NutreStore</other_name>
    <other_name>Resource</other_name>
    <other_name>GlutaSolve</other_name>
    <other_name>Sympt-X G.I.</other_name>
    <other_name>Sympt-X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Cryotherapy (ice chips)</intervention_name>
    <description>Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>100 mg by vein or mouth three times a day from Day -1.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>Stem cells administered by vein on Day 0.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.</description>
    <arm_group_label>Cohort A: Diffuse Large B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Cohort B: Hodgkin's Lymphoma</arm_group_label>
    <arm_group_label>Cohort C: T-Cell Lymphoma</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 15-65

          2. Patients with: DLBCL with one of the following: 1. Primary refractory (no CR to 1st
             line); 2. High-risk relapse (CR1 &lt;6 months, secondary IPI &gt;1 or high LDH); or, 3.
             Refractory relapse: No response (SD or PD) to &gt;/= 1 line of salvage.

          3. Hodgkin's with one of the following: 1. Primary refractory (no CR to 1st line or PD
             within 3 months); 2. High-risk relapse (CR1 &lt;1 year, extranodal relapse or B
             symptoms); or, 3. Refractory relapse: No response (SD or PD) to &gt;/= 1 line of salvage.

          4. T-NHL with one of the following: 1. Primary refractory (&lt;/= CR to 1st line or relapse
             within 6 months); or, 2. Nonresponsive (SD/PD) to &gt;/= 1 line of salvage.

          5. Adequate renal function, as defined by estimated serum creatinine clearance &gt;/= 50
             ml/min and/or serum creatinine &lt;/= 1.8 mg/dL

          6. Adequate hepatic function (SGOT and/or serum glutamate pyruvate transaminase (SGPT)
             &lt;/= 3 x upper limit of normal (ULN); bilirubin and ALP &lt;/= 2 x ULN

          7. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced
             vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO)
             (corrected for Hgb) &gt;/= 50%

          8. Adequate cardiac function with left ventricular ejection fraction &gt;/= 40%. No
             uncontrolled arrhythmias or symptomatic cardiac disease

          9. PS &lt;2

         10. Negative Beta human chorionic gonadotropin (HCG) in woman with child-bearing potential

        Exclusion Criteria:

          1. Grade &gt;/= 3 non-hematologic toxicity from prior therapy that has not resolved to &lt;/=
             G1

          2. Prior whole brain irradiation

          3. Corrected QT interval (QTc) longer than 500 ms

          4. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA &gt;/= 10,000
             copies/mL, or &gt;/= 2,000 IU/mL)

          5. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
             hepatitis C or positive hepatitis C serology

          6. Active infection requiring parenteral antibiotics

          7. HIV infection, unless receiving effective antiretroviral therapy with undetectable
             viral load and normal cluster of differentiation 4 (CD4) counts

          8. Radiation therapy in the month prior to enroll
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago Nieto, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Refractory/Relapsed Lymphoma</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>T-cell Lymphoma</keyword>
  <keyword>Palifermin</keyword>
  <keyword>Kepivance</keyword>
  <keyword>Panobinostat</keyword>
  <keyword>LBH589B</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Gemcitabine Hydrochloride</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Myleran</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Alkeran</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Caphosol</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Enterex</keyword>
  <keyword>Glutapak-10</keyword>
  <keyword>NutreStore</keyword>
  <keyword>Resource</keyword>
  <keyword>GlutaSolve</keyword>
  <keyword>Sympt-X G.I.</keyword>
  <keyword>Sympt-X</keyword>
  <keyword>Pyridoxine</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

